Axcella shares are trading higher after the company announced it was granted a patent for long COVID fatigue treatment.
Portfolio Pulse from Benzinga Newsdesk
Axcella has been granted a patent for a treatment for long COVID fatigue, leading to a rise in its share prices.

August 29, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axcella's stock is trading higher after the company was granted a patent for long COVID fatigue treatment.
The granting of a patent for a new treatment for long COVID fatigue is a significant development for Axcella. This could potentially open up a new revenue stream for the company, which is likely why the stock is trading higher. However, the actual impact will depend on the success of the treatment in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100